Description: Lortinib is a pharmaceutical product available in tablet form, with each tablet containing 150 mg of Erlotinib as the active ingredient. Erlotinib is an orally administered tyrosine kinase inhibitor that is widely used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer.

Composition: Each tablet of Lortinib comprises 150 mg of Erlotinib hydrochloride, along with various excipients to ensure proper formulation and stability.

Uses: Lortinib is prescribed for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) and locally advanced, unresectable, or metastatic pancreatic cancer. Erlotinib targets specific signaling pathways involved in cancer cell growth, helping to inhibit tumor progression.

Usage and Dosage: The dosage and administration of Lortinib are determined by the treating healthcare professional based on the patient’s specific medical condition, overall health, and other relevant factors. Patients are advised to adhere strictly to the prescribed dosage and schedule.

Storage Conditions: Lortinib tablets should be stored in a cool, dry place, away from direct sunlight, and at a controlled room temperature. Adhering to the storage instructions provided by the manufacturer is essential to maintain the stability and effectiveness of the product. Keep the medication out of the reach of children.

Mechanism of Action: Erlotinib, the active ingredient in Lortinib, is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) pathway. By inhibiting this pathway, Erlotinib interferes with the signals that promote cancer cell growth and division, ultimately slowing down or halting the progression of the disease.

Contraindications: Lortinib is contraindicated in individuals with known hypersensitivity to Erlotinib or any components of the formulation. It is important to inform healthcare providers of any existing allergies or adverse reactions to medications.

Interactions: Erlotinib may interact with other medications, and it is crucial for healthcare professionals to be aware of any concurrent drug therapies. Specific drugs, such as those affecting liver enzyme systems, may interact with Erlotinib, potentially affecting its efficacy or increasing the risk of adverse effects.

Adverse Reactions: Common adverse reactions associated with Lortinib may include skin rash, diarrhea, fatigue, anorexia, and stomatitis. Patients should promptly report any unusual or severe side effects to their healthcare provider.

Patients are advised to consult with their healthcare provider for personalized information regarding the use of Lortinib, as individual responses to medication can vary. Regular communication with the healthcare team is important for optimal management and monitoring during cancer treatment.